Breast Cancer Foundation NZ
LYT-100 in Healthy Volunteers and BCRL
This study is investigating the safety, tolerability and pharmacokinetic (PK) profile of LYT-100 in healthy volunteers and in those with breast cancer-related lymphoedema.
This study is investigating the safety, tolerability and pharmacokinetic (PK) profile of LYT-100 in healthy volunteers and in those with breast cancer-related lymphoedema.
Who is it for?
Healthy volunteers
- Male or female between 18 and 75 years old (inclusive) at the time of screening.
- In good general health at screening, free from clinically significant unstable medical, surgical or psychiatric illness, at the discretion of the Investigator.
Patients with breast cancer-related lymphoedema
- Female or male between 18 and 80 years old (inclusive) at the time of informed consent.
- At least six months since any type of breast cancer surgery (excluding fine needle aspiration biopsy [FNA]), at the time of study screening. No intention to have breast reconstructive surgery, nipple reconstruction and/or tattooing during the course of the study.
- At least three months since completion of all types of treatment for breast cancer, including but not limited to neoadjuvant, radiotherapy, chemotherapy and immunotherapy, at the time of study screening.
- At least three months treatment of stable adjuvant treatment with hormonal or anti-HER2 therapy at the time of screening, with no planned changes to this therapy throughout the duration of the study.
- Diagnosis of primary breast cancer, and without evidence of recurrence of breast cancer and/or metastasis for at least six months since breast cancer surgery, as determined at screening and baseline.
- Documented evidence of Stage 1 or 2 lymphoedema.
- Receiving standard of care compression or agreeable to using care compression, or no compression at all = four weeks prior to screening and throughout the study.
Study details
Part 1 is a multiple ascending dose trial in healthy volunteers (HV) of LYT-100 to determine safety, tolerability, and pharmacokinetic (PK) profile under fed conditions.
Part 2 is a single dose safety, tolerability, and PK trial in HV of LYT-100 under fasted conditions.
Part 3 is a trial of up to six-months duration for safety, tolerability, PK, biomarkers and exploratory clinical assessments in breast cancer patients with secondary lymphoedema.
Australia
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Supportive Care
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.